From Bucharest to Warwick: Tudor Onose’s Synthetic Biology Journey

Tudor Onose’s journey into synthetic biology began with iGEM. As a team member in 2020 and 2021, and later as a mentor to the 2024 Warwick team, he’s seen the competition from two sides. Now a Ph.D. student at the University of Warwick, Tudor studies bacterial electrophysiology, and reflects in this interview with Andreea Cernei about team-building, mentorship and the future of synbio in Romania.

From Idea to Impact: Highlights from the 2025 Venture Creation La

The 2025 Venture Creation Lab (VCL), held from April 21st to May 16th, hosted by iGEM Startups, brought together aspiring biotech entrepreneurs from around the world to take their first concrete steps toward building a synthetic biology startup. Following the momentum of the BioHackathon, the VCL provided a four-week program designed to turn early ideas into viable venture concepts through lectures, workshops and personalized mentorship.

Understanding Impact Investing and Navigating as Early-Stage BioTech Entrepreneurs: Insights from Jonty Corrin

Jonty Corrin started his career in academia as a bioscientist, but his entrepreneurial journey began during his final year of undergraduate work. While his first startup didn’t thrive, it sparked a passion for early-stage startups and their growth. Along the way, he connected with Nucleate UK, a student-led, nonprofit organization that helps early-stage biotech founders translate academic research into real-world startups with dynamic support. 

Yizhi ‘Patrick’ Cai: An iGEMer who is unraveling nature’s design rules to create synthetic life

Professor Yizhi ‘Patrick’ Cai, of the University of Manchester, credits iGEM for introducing him to synthetic biology and giving him the experience, colleagues and connections necessary for a successful academic career. Here, Professor Cai describes his many and varied iGEM experiences that helped shape and influence his career, and offers insights into the future of synthetic biology for the iGEMers of today.